Sunitinib

Sunitinib
Clinical data
Trade names	Sutent, others
Other names	SU11248
AHFS/Drugs.com	Monograph
MedlinePlus	a607052
License data	EU EMA: by INN; US DailyMed: Sunitinib; US FDA: Sunitinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L01EX01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Unaffected by food
Protein binding	95%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	40 to 60 hours (sunitinib); 80 to 110 hours (metabolite)
Excretion	Fecal (61%) and kidney (16%)
Identifiers
	IUPAC name N-(2-Diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;
CAS Number	557795-19-4 ; as salt: 341031-54-7 ;
PubChem CID	5329102; as salt: 6456015;
IUPHAR/BPS	5713;
DrugBank	DB01268 ; as salt: DBSALT000166;
ChemSpider	4486264 ; as salt: 4958254;
UNII	V99T50803M; as salt: LVX8N1UT73 ;
KEGG	D08552 ; as salt: D06402;
ChEBI	CHEBI:38940 ;
ChEMBL	ChEMBL535 ; as salt: ChEMBL1567;
CompTox Dashboard (EPA)	DTXSID1041134 ;
Chemical and physical data
Formula	C22H27FN4O2
Molar mass	398.482 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C;
	InChI InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- ; Key:WINHZLLDWRZWRT-ATVHPVEESA-N ; ; as salt: InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1; Key:LBWFXVZLPYTWQI-IPOVEDGCSA-N;
	(what is this?) (verify)

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication.^[2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.^[3]

As of August 2021, sunitinib is available as a generic medicine in the US.^[4]

^ "SUNITINIB MSN sunitinib (as malate) 50 mg hard capsule bottle (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 16 October 2022. Retrieved 19 April 2023.
^ ^a ^b "Sutent- sunitinib malate capsule". DailyMed. Archived from the original on 23 March 2021. Retrieved 7 April 2021.
^ Cite error: The named reference FDA was invoked but never defined (see the help page).
^ "Sunitinib malate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 25 September 2021. Retrieved 24 September 2021.

[1] "SUNITINIB MSN sunitinib (as malate) 50 mg hard capsule bottle (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 16 October 2022. Retrieved 19 April 2023.

[Sutent_FDA_label-2] "Sutent- sunitinib malate capsule". DailyMed. Archived from the original on 23 March 2021. Retrieved 7 April 2021.

[FDA-3] Cite error: The named reference FDA was invoked but never defined (see the help page).

[4] "Sunitinib malate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 25 September 2021. Retrieved 24 September 2021.

[1]

[2]

[3]

[4]